MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Interest Expense 2011-2026 | SRDX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 310 K | 133 K | 152 K | - | - | - | 496 K | 133 K | 137 K | 228 K | 401 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 496 K | 133 K | 249 K |
Quarterly Interest Expense Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 879 K | 881 K | 896 K | - | 884 K | 884 K | 826 K | - | 145 K | 129 K | 136 K | - | 59 K | 59 K | 60 K | 99 K | 29 K | 60 K | 40 K | 112 K | 38 K | 40 K | 37 K | - | - | 37 K | - | - | - | - | - | - | -6 K | 361 K | - | 496 K | -40 K | 543 K | -7 K | 125 K | 125 K | -7 K | - | 1.34 M | 2 K | 163 K | 1.18 M | 172 K | 2 K | 162 K | 8 K | 379 K | 171 K | 8 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 M | -40 K | 281 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
81 M | $ 116.92 | 2.67 % | $ 35.5 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.92 | 1.41 % | $ 955 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K |  Israel |
 |
Danaher Corporation
DHR
|
-222 M | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 51.17 | 2.09 % | $ 3.06 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Guardant Health
GH
|
-10.5 M | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Illumina
ILMN
|
-292 M | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 116.94 | 1.19 % | $ 5.47 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 80.03 | 2.5 % | $ 5.4 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 198.81 | 1.02 % | $ 22.1 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.22 | 1.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 5.17 | -3.18 % | $ 4.07 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 210.83 | 0.75 % | $ 20.7 B | USA |